Jon B. Toledo: Role: ConceptualizationRole: Formal analysisRole: InvestigationRole: Writing – original
draftRole: Writing – review & editing
Tanweer Rashid: Role: Formal analysisRole: MethodologyRole: SoftwareRole: Writing – review & editing
Hangfan Liu: Role: MethodologyRole: SoftwareRole: Writing – review & editing
Lenore Launer:
ORCID: https://orcid.org/0000-0002-3238-7612
Role: Writing – review & editing
Leslie M. Shaw: Role: Writing – review & editing
Susan R. Heckbert: Role: Writing – review & editing
Michael Weiner: Role: Writing – review & editing
Sudha Seshadri: Role: Writing – review & editing
Mohamad Habes:
ORCID: https://orcid.org/0000-0001-9447-5805
Role: ConceptualizationRole: MethodologyRole: ResourcesRole: SupervisionRole: Writing
– original draftRole: Writing – review & editing
Kensaku Kasuga: Role: Editor
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS One
Journal ID (publisher-id): plos
Title:
PLOS ONE
Publisher:
Public Library of Science
(San Francisco, CA USA
)
ISSN
(Electronic):
1932-6203
Publication date
(Electronic):
3
November
2022
Publication date Collection: 2022
Volume: 17
Issue: 11
Electronic Location Identifier: e0276392
Affiliations
[1
]
Department of Neurology, University of Florida College of Medicine, Gainesville, Florida,
United States of America
[2
]
Department of Neurology Houston Methodist Hospital, Houston, Texas, United States
of America
[3
]
Neuroimage Analytics Laboratory (NAL) and the Biggs Institute Neuroimaging Core (BINC),
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, University of
Texas Health Science Center San Antonio (UTHSCSA), San Antonio, Texas, United States
of America
[4
]
Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania,
Philadelphia, Pennsylvania, United States of America
[5
]
Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National
Institute on Aging, Bethesda, Maryland, United States of America
[6
]
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University
of Pennsylvania, Philadelphia, Pennsylvania, United States of America
[7
]
Department of Epidemiology and Cardiovascular Health Research Unit, University of
Washington, Seattle, Washington, United States of America
[8
]
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative
Diseases, San Francisco, California, United States of America
[9
]
Department of Radiology, University of California, San Francisco, California, United
States of America
[10
]
Department of Medicine, University of California, San Francisco, California, United
States of America
[11
]
Department of Psychiatry, University of California, San Francisco, California, United
States of America
[12
]
Department of Neurology, University of California, San Francisco, California, United
States of America
[13
]
Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of
Texas Health Sciences Center, San Antonio, Texas, United States of America
Niigata University, JAPAN
Author notes
Competing Interests: Dr. Shaw provides quality control oversight for the Roche Electrosys immunoassay platform
as part of the ADNI-3 study. Dr. Weiner has served on the Scientific Advisory Boards
for Alzheon, Inc., Accera, Merck, Nestle (Nolan), PCORI (PPRN), Eli Lilly, Delfino
Logic Ltd. (for Merck), Dolby Ventures, Brain Health Registry, and ADNI. He served
on the editorial boards for Alzheimer’s & Dementia and MRI. He has provided consulting
and/or acted as a speaker/lecturer to Synarc, Pfizer, Accera, Inc., Alzheimer’s Drug
Discovery Foundation (ADDF), Merck, BioClinica, Eli Lilly, Howard University, Guidepoint,
Denali Therapeutics, Nestle/Nestec, GLG Research, Atheneum Partners, BIONEST Partners,
American Academy of Neurology (AAN), and Society for Nuclear Medicine and Molecular
Imaging (SNMMI). This does not alter our adherence to PLOS ONE policies on sharing
data and materials. Other authors report no competing interests.
¶ Membership of the Alzheimer’s Disease Neuroimaging Initiative Group is listed in
the Acknowledgments.
Author information
Article
Publisher ID:
PONE-D-22-21443
DOI: 10.1371/journal.pone.0276392
PMC ID: 9632811
PubMed ID: 36327215
SO-VID: 88ebe491-35f9-440b-8fab-3eda398ee93c
Copyright © © 2022 Toledo et al
License:
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funded by:
National Institutes of Health
Award ID: 1R01AG080821, P30AG066546, 1U24AG074855
Funded by:
funder-id http://dx.doi.org/10.13039/100020065, San Antonio Medical Foundation;
Award ID: SAMF – 1000003860
Funded by:
Edmond J. Safra Fellowship
Award Recipient
:
Jon B. Toledo
Funded by:
funder-id http://dx.doi.org/10.13039/100007333, Alzheimer’s Disease Neuroimaging Initiative;
Award ID: National Institutes of Health Grant U01 AG024904
Funded by:
DOD ADNI
Award ID: Department of Defense award number W81XWH-12-2-0012
This study was partly supported by the National Institutes of Health (NIH) grant numbers
1R01AG080821, P30AG066546, 1U24AG074855, and the San Antonio Medical Foundation grant
SAMF – 1000003860. JBT is the Harrison Endowed Research Director at the Nantz National
Alzheimer Center and has received support from the Edmond J. Safra Fellowship in Movement
Disorders. Data collection and sharing for this project were funded by the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904)
and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded
by the National Institute on Aging, the National Institute of Biomedical Imaging and
Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s
Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.;
Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals,
Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated
company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy
Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development
LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx
Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.;
Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics.
The Canadian Institutes of Health Research is providing funds to support ADNI clinical
sites in Canada. Private sector contributions are facilitated by the Foundation for
the National Institutes of Health (
www.fnih.org). The grantee organization is the Northern California Institute for Research and
Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute
at the University of Southern California. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
